Clinical Trials Logo

Carcinoma, Renal Cell clinical trials

View clinical trials related to Carcinoma, Renal Cell.

Filter by:

NCT ID: NCT00293527 Withdrawn - Renal Cancer Clinical Trials

Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

This study will determine the response rate of daily low dose interferon-alpha-2b in patients with metastatic or unresectable clear cell renal cell carcinoma.

NCT ID: NCT00293501 Active, not recruiting - Kidney Cancer Clinical Trials

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Start date: December 2005
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with metastatic kidney cancer that cannot be removed by surgery.

NCT ID: NCT00291369 Completed - Clinical trials for Metastatic Renal Cell Carcinoma

Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis

Start date: December 1999
Phase: Phase 3
Study type: Interventional

The PERCY Quattro trial has been designed to evaluate the survival benefit of two cytokine treatments, Interleukin-2 (IL2) and/or alpha interferon (IFN), for patients with intermediate chance of response in metastatic renal cell carcinoma. Eligible patients will be randomly assigned in a two-by-two factorial design to either medroxyprogesterone (MPA), subcutaneous IFN, subcutaneous IL2, or a combination of IFN and IL2. The primary objective of the study is overall survival; secondary objectives are progression-free survival, response rate, toxicity, and quality of life.

NCT ID: NCT00289146 Terminated - Kidney Cancer Clinical Trials

Comparison of Immune Response Following Surgical Management of Renal Tumors

Start date: November 2005
Phase: N/A
Study type: Observational

Examine the effects of renal surgery on the immune system.

NCT ID: NCT00282048 Completed - Clinical trials for Carcinoma, Renal Cell

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Start date: March 2006
Phase: Phase 2
Study type: Interventional

To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).

NCT ID: NCT00278395 Completed - Clinical trials for Stage IV Renal Cell Cancer

Vorinostat in Treating Patients With Kidney Cancer

Start date: October 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well vorinostat works in treating patients with advanced kidney cancer. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking blood flow to the tumor.

NCT ID: NCT00278174 Completed - Kidney Cancer Clinical Trials

Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer

Start date: February 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer. PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients with metastatic kidney cancer.

NCT ID: NCT00277316 Terminated - Clinical trials for Renal Cell Carcinoma

Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

Start date: December 2005
Phase: Phase 2
Study type: Interventional

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic clear cell renal cell carcinoma (RCC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

NCT ID: NCT00277017 Completed - Cancer Clinical Trials

Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma

Start date: September 2000
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate a therapy combining the established FUNIL regimen with Thalidomide. We want to see how well the therapy works, if it can be easily done, and how well the body handles the treatment. We also wish to see if the addition of Thalidomide will increase the effectiveness of the already established treatment regimen.

NCT ID: NCT00276835 Completed - Kidney Cancer Clinical Trials

Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer

Start date: November 2005
Phase: Phase 0
Study type: Interventional

RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells, including natural killer cells, to kill melanoma or kidney cancer cells. Giving genistein together with interleukin-2 may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving genistein together with interleukin-2 works in treating patients with metastatic melanoma or kidney cancer.